Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices 80107 

microbiologic cure, (3) Using existing 

laboratory specimens, monitor genetic 

mutations associated with macrolide or 

fluroquinolone antibiotic resistance. 

Data captured on the standardized 

Case Report Form will be analyzed to 

determine outcomes from usage of 

second-line antibiotic therapy for 

M.gentialium. These data may inform 

future CDC STD Treatment Guidelines. 

There are an estimated 100 respondents 

(anticipated to report once per year) 

who will be clinicians in private and 

public health care settings. The data 

collection is necessary as there are no 

current national recommendations for 

patients who fail current CDCrecommended therapy for M. 

genitalium. Each case report form is 

anticipated to take up to 60 minutes to 

complete. This data collection provides 

CDC with information to determine 

which second-line treatments are most 

clinically effective, as well as 

determining antibiotic resistance 

patterns of M. genitalium throughout the 

US. There are no costs to respondents 

other than their time. The estimated 

annualized burden hours for this data 

collection are 100 hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name No. of Respondents 

No. responses 

per respondent 

Average burden per response 

(in hours) 

Physician or Nurse Practitioner.M. genitalium Treatment Failure Registry Case Report Form 100 1 1 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2020–27326 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, Disability, 

and Injury Prevention and Control Special 

Emphasis Panel (SEP)-DP21–002, 

Epidemiologic Cohort Study of Interstitial 

Cystitis. 

Date: March 30, 2021. 

Time: 10:00 a.m.–6:00 p.m., EST. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman Ph.D., Scientific Review Officer, CDC, 

4770 Buford Highway, Mailstop F80, Atlanta, 

Georgia 30341, Telephone: (770) 488–6511, 

JRaman@cdc.gov. 

The Director, Strategic Business Initiatives 

Unit, Office of the Chief Operating Officer, 

Centers for Disease Control and Prevention, 

has been delegated the authority to sign 

Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities, for both 

the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives 

Unit,Office of the Chief Operating 

Officer,Centers for Disease Control and 

Prevention. 

[FR Doc. 2020–27229 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Centers for Disease Control and 

Prevention (CDC)/Health Resources 

and Services Administration (HRSA) 

Advisory Committee on HIV, Viral 

Hepatitis and STD Prevention and 

Treatment (CHACHSPT); Notice of 

Charter Renewal 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of charter renewal. 

SUMMARY: This gives notice under the 

Federal Advisory Committee Act of 

October 6, 1972, that the Centers for 

Disease Control and Prevention (CDC)/ 

Health Resources and Services 

Administration (HRSA) Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment 

(CHACHSPT), Centers for Disease 

Control and Prevention, Department of 

Health and Human Services, has been 

renewed for a 2-year period through 

November 25, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Jonathan Mermin, MD, MPH, 

Designated Federal Officer, Centers for 

Disease Control and Prevention (CDC)/ 

Health Resources and Services 

Administration (HRSA) Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment 

(CHACHSPT), CDC, HHS, 1600 Clifton 

Road NE, Mailstop US8–6, Atlanta, 

Georgia 30329–4027; Telephone (404) 

639–8000, JMermin@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

Director, Strategic Business Initiatives 

Unit, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, has been delegated the 

authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2020–27227 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 


jbell on DSKJLSW7X2PROD with NOTICES